Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study

Annals of Surgery

Volumn 248, Issue 2, 2008, Pages 145-151

  Linehan, David C ^a,d   Tan, Marcus C B ^a   Strasberg, Steven M ^a   Drebin, Jeffrey A ^a   Hawkins, William G ^a   Picus, Joel ^a   Myerson, Robert J ^a   Malyapa, Robert S ^a   Hull, Michael ^b   Trinkaus, Kathryn ^c   Tan, Benjamin R ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d Section of Hepato Pancreato Biliary and GI Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTADENOCARCINOMA; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VOLUME; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METHODOLOGY; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 49849089276     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318181e4e9     Document Type: Article

References (14)

1. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903.
2. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59:2006-2010.
3. Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/-5 fluorouracil. Int JRadiat Oncol Biol Phys. 1993;26: 483-489.
4. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
5. Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1991; 21:1137-1143.
6. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-633.
7. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297:267-277.
9. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemo- radiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000;179:367-371.
10. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant che- moradiation therapy after pancreaticoduodenectomy for pancreatic ade- nocarcinoma. Am J Surg. 2003;185:476-480.
11. Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 1988;41:1209 -1213.
12. Deleted in proof.
13. Saidi R, Williams F, Silberberg B, et al. Expression of interferon receptors in pancreatic cancer: Identification of a novel prognostic factor. Surgery. 2006;139:743-748.
14. Schmidt J, Jager D, Hoffman K, et al. Impact of Interferon-alpha in combined chemoradioimmunotherapy for panceatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother. 2007; 30:108-115.